Anticytokine approaches in pulmonary fibrosis: bringing factors into focus
The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper out...
Gespeichert in:
| Veröffentlicht in: | Thorax 1997-03, Vol.52 (3), p.294-296 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 296 |
|---|---|
| container_issue | 3 |
| container_start_page | 294 |
| container_title | Thorax |
| container_volume | 52 |
| creator | Coker, R K Laurent, G J |
| description | The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper outlines the role of cytokines in the pathogenesis of pulmonary fibrosis and concludes that there are compelling reasons to explore anticytokine therapeutic approaches. It also proposes criteria that will enable us to evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors. |
| doi_str_mv | 10.1136/thx.52.3.294 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1758516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3974798051</sourcerecordid><originalsourceid>FETCH-LOGICAL-b506t-91318f5065da41375b8ceeba4076c53b7854ea61ae597b8f844ed450a60af9843</originalsourceid><addsrcrecordid>eNp9kc1rFDEAxYModa3evAoDil6cNZl8exDKYtVa9LJ6DZls0s12JpkmGWn_e1N2WdSDEEjg_Xi8vAfAcwSXCGH2rmxvl7Rb4mUnyQOwQISJFneSPQQLCAlsGebsMXiS8w5CKBDiJ-BEQokx7Rbg4iwUb-5KvPbBNnqaUtRma3PjQzPNwxiDTneN832K2ef3TZ98uKqncdqUmO65EhsXzZyfgkdOD9k-O9yn4Mf5x_Xqc3v5_dOX1dll21PISisRRsLVJ91ogjCnvTDW9ppAzgzFPReUWM2QtlTyXjhBiN0QCjWD2klB8Cn4sPed5n60G2NDSXpQU_Jjzaqi9upvJfituoq_FOJUUMSqweuDQYo3s81FjT4bOww62DhnxYWsVSJZwZf_gLs4p1A_V704Ip2sZVfq7Z4ytaOcrDtGQVDdL6TqQop2CqtqW_EXf8Y_wodJqv7qoOts9OCSDsbnI9axTjDKK9buMZ-LvT3KOl0rxmur6tvPlfrK0Xp9AbE6r_ybPd-Pu_8H_A3j1bWl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771429146</pqid></control><display><type>article</type><title>Anticytokine approaches in pulmonary fibrosis: bringing factors into focus</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Coker, R K ; Laurent, G J</creator><creatorcontrib>Coker, R K ; Laurent, G J</creatorcontrib><description>The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper outlines the role of cytokines in the pathogenesis of pulmonary fibrosis and concludes that there are compelling reasons to explore anticytokine therapeutic approaches. It also proposes criteria that will enable us to evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thx.52.3.294</identifier><identifier>PMID: 9093352</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Antibodies - therapeutic use ; Antisense Elements (Genetics) - therapeutic use ; Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Cytokines - antagonists & inhibitors ; Cytokines - metabolism ; Growth Inhibitors - therapeutic use ; Humans ; Mannosephosphates - therapeutic use ; Medical sciences ; Pneumology ; Pulmonary Fibrosis - immunology ; Pulmonary Fibrosis - therapy ; Transforming Growth Factor beta - genetics ; Transforming Growth Factor beta - metabolism ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Thorax, 1997-03, Vol.52 (3), p.294-296</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Mar 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b506t-91318f5065da41375b8ceeba4076c53b7854ea61ae597b8f844ed450a60af9843</citedby><cites>FETCH-LOGICAL-b506t-91318f5065da41375b8ceeba4076c53b7854ea61ae597b8f844ed450a60af9843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758516/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758516/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2628657$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9093352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coker, R K</creatorcontrib><creatorcontrib>Laurent, G J</creatorcontrib><title>Anticytokine approaches in pulmonary fibrosis: bringing factors into focus</title><title>Thorax</title><addtitle>Thorax</addtitle><description>The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper outlines the role of cytokines in the pathogenesis of pulmonary fibrosis and concludes that there are compelling reasons to explore anticytokine therapeutic approaches. It also proposes criteria that will enable us to evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors.</description><subject>Antibodies - therapeutic use</subject><subject>Antisense Elements (Genetics) - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Cytokines - antagonists & inhibitors</subject><subject>Cytokines - metabolism</subject><subject>Growth Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Mannosephosphates - therapeutic use</subject><subject>Medical sciences</subject><subject>Pneumology</subject><subject>Pulmonary Fibrosis - immunology</subject><subject>Pulmonary Fibrosis - therapy</subject><subject>Transforming Growth Factor beta - genetics</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1rFDEAxYModa3evAoDil6cNZl8exDKYtVa9LJ6DZls0s12JpkmGWn_e1N2WdSDEEjg_Xi8vAfAcwSXCGH2rmxvl7Rb4mUnyQOwQISJFneSPQQLCAlsGebsMXiS8w5CKBDiJ-BEQokx7Rbg4iwUb-5KvPbBNnqaUtRma3PjQzPNwxiDTneN832K2ef3TZ98uKqncdqUmO65EhsXzZyfgkdOD9k-O9yn4Mf5x_Xqc3v5_dOX1dll21PISisRRsLVJ91ogjCnvTDW9ppAzgzFPReUWM2QtlTyXjhBiN0QCjWD2klB8Cn4sPed5n60G2NDSXpQU_Jjzaqi9upvJfituoq_FOJUUMSqweuDQYo3s81FjT4bOww62DhnxYWsVSJZwZf_gLs4p1A_V704Ip2sZVfq7Z4ytaOcrDtGQVDdL6TqQop2CqtqW_EXf8Y_wodJqv7qoOts9OCSDsbnI9axTjDKK9buMZ-LvT3KOl0rxmur6tvPlfrK0Xp9AbE6r_ybPd-Pu_8H_A3j1bWl</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>Coker, R K</creator><creator>Laurent, G J</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970301</creationdate><title>Anticytokine approaches in pulmonary fibrosis: bringing factors into focus</title><author>Coker, R K ; Laurent, G J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b506t-91318f5065da41375b8ceeba4076c53b7854ea61ae597b8f844ed450a60af9843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibodies - therapeutic use</topic><topic>Antisense Elements (Genetics) - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Cytokines - antagonists & inhibitors</topic><topic>Cytokines - metabolism</topic><topic>Growth Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Mannosephosphates - therapeutic use</topic><topic>Medical sciences</topic><topic>Pneumology</topic><topic>Pulmonary Fibrosis - immunology</topic><topic>Pulmonary Fibrosis - therapy</topic><topic>Transforming Growth Factor beta - genetics</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coker, R K</creatorcontrib><creatorcontrib>Laurent, G J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coker, R K</au><au>Laurent, G J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticytokine approaches in pulmonary fibrosis: bringing factors into focus</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>52</volume><issue>3</issue><spage>294</spage><epage>296</epage><pages>294-296</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper outlines the role of cytokines in the pathogenesis of pulmonary fibrosis and concludes that there are compelling reasons to explore anticytokine therapeutic approaches. It also proposes criteria that will enable us to evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><pmid>9093352</pmid><doi>10.1136/thx.52.3.294</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 1997-03, Vol.52 (3), p.294-296 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1758516 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibodies - therapeutic use Antisense Elements (Genetics) - therapeutic use Biological and medical sciences Chronic obstructive pulmonary disease, asthma Cytokines - antagonists & inhibitors Cytokines - metabolism Growth Inhibitors - therapeutic use Humans Mannosephosphates - therapeutic use Medical sciences Pneumology Pulmonary Fibrosis - immunology Pulmonary Fibrosis - therapy Transforming Growth Factor beta - genetics Transforming Growth Factor beta - metabolism Tumor Necrosis Factor-alpha - immunology |
| title | Anticytokine approaches in pulmonary fibrosis: bringing factors into focus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A17%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticytokine%20approaches%20in%20pulmonary%20fibrosis:%20bringing%20factors%20into%20focus&rft.jtitle=Thorax&rft.au=Coker,%20R%20K&rft.date=1997-03-01&rft.volume=52&rft.issue=3&rft.spage=294&rft.epage=296&rft.pages=294-296&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thx.52.3.294&rft_dat=%3Cproquest_pubme%3E3974798051%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771429146&rft_id=info:pmid/9093352&rfr_iscdi=true |